Titre:
  • Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Auteur:Goss, Paul; Ingle, James N; Martino, S; Robert, Nicholas J; Muss, Hyman B; Piccart-Gebhart, Martine; Castiglione, Monica; Tu, Dongsheng; Shepherd, L; Pritchard, Kathleen; Livingston, Robert; Davidson, Nancy E; Norton, Larry; Perez, Edith A; Abrams, Jeffrey S; Cameron, David A; Palmer, Michael J; Pater, Joseph L
Informations sur la publication:Journal of the National Cancer Institute, 97, 17, page (1262-1271)
Statut de publication:Publié, 2005-09
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Aged
Antineoplastic Agents, Phytogenic -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Aromatase Inhibitors -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Incidence
Lymphatic Metastasis
Middle Aged
Nitriles -- adverse effects
Nitriles -- therapeutic use
Postmenopause
Receptors, Estrogen -- analysis
Receptors, Progesterone -- analysis
Survival Analysis
Tamoxifen -- adverse effects
Tamoxifen -- therapeutic use
Treatment Outcome
Triazoles -- adverse effects
Triazoles -- therapeutic use
Note générale:Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langue:Anglais
Identificateurs:urn:issn:0027-8874
info:doi/10.1093/jnci/dji250
info:pii/97/17/1262
info:scp/24744450378
info:pmid/16145047